Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative and absolute bioavailability of AMY109 in healthy male volunteers
jRCT2071220046Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-IL-8 monoclonal antibody in endometriosis, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety (adverse events and adverse drug reactions), Vital signs and 4 more. Started Oct 2022; status: completed.
02
Drugs
anti-IL-8 monoclonal antibody
03
Conditions
endometriosis
Beyond the preview
Go deeper on jRCT2071220046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220046.